Recent Pharmaceuticals releases

[PRESSWIRE] Weimar, Germany - 29 October, 2018 -- The renewed interest in anti-GBM disease is spurred by the detection of autoantibodies in other forms of glomerulonephritis and has led to an exciting development in studies on pathogenesis as well as diagnosis and management. The newly published review [1] by Professor Mårten Segelmark, gives a comprehensive update on Anti-GBM disease subgroups, pathogenesis and therapies. “A must-read for all nephrologist”, explains Professor Denis Fouque, editor-in-chief of Nephrology Dialysis and Transplantation (NDT), the journal in which the review was published.

[PRESSWIRE] SEATTLE and VANCOUVER, British Columbia, Sept. 27, 2018 -- Achieve Life Sciences, Inc. (NASDAQ :ACHV ), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced results of a clinical study evaluating the effect of food on the bioavailability of a new formulation for cytisine.

[PRESSWIRE] ‘s-Hertogenbosch, The Netherlands - 5 July, 2018 -- A total grant sum of EUR 2 million has been awarded to a multidisciplinary EUROSTARS consortium. The EUROSTARS project is titled "Treatment Response Monitoring for Cancer Immunotherapies Using Immune Repertoire Analysis” and named IMMUNOMONITOR.

[PRESSWIRE] Germany - 27 June, 2018 -- Kidney diseases have so far been underestimated in many respects: most people are not aware of their impaired kidney function. In general, kidney diseases are “silent diseases”, most often there are no apparent early symptoms. Many people with kidney diseases are not aware that they have been living with higher risks of cardiovascular diseases, infections, hospitalizations, and of course kidney failure which requires dialysis or transplantation.

 [PRESSWIRE] LONDON, June 19, 2018 -- While the automotive and electronics industries, among others, have been relatively fast in adopting robotics, pharma has been lagging behind.

[PRESSWIRE] Boston, MA - June 12, 2018 -- Zaluvida a global life science group, announced today the formation of a Scientific Advisory Board (SAB) to inform the Human Health Research & Development department about the latest research, scientific methods, and opportunities for weight-loss management, and help further technology and product development for the company.

[PRESSWIRE] London, United Kingdom -- 11 April, 2018 - To coincide with this month’s WORLD MALARIA DAY and THECOMMONWEALTH CONFERENCE which has malaria prevention high on the agenda, Vectorcide International Ltd www.vectorcide.co.uk - a private UK company - announces their breakthrough-coating product (containing a WHO approved active ingredient) to combat and kill the female mosquito: the carrier of diseases such as Malaria, Dengue, Zika, etc.

 [PRESSWIRE] AACHEN, Germany and LEUVEN, Belgium, April 9, 2018 -- Grünenthal, the Katholieke Universiteit Leuven's Centre for Drug Design and Discovery (CD3) and the Laboratory of Ion Channel Research (LICR) announced today that they have entered into a research collaboration for the development of novel non-opioid drug candidates for the treatment of painful diseases with a high unmet medical need.

 [PRESSWIRE] HUDDINGE, Sweden, March 23, 2018 -- Karo Pharma has decided to support Operation Smile with a donation of 2,5 MSEK.

 [PRESSWIRE] LONDON, March 5, 2018 -- PharmaBoardroom today releases its new 60-page Healthcare & Life Sciences Review Brazil 2018.